Rita Ehrlich1, Thomas A Ciulla, Adam M Moss, Alon Harris. 1. Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202, USA. ritaehrlich@gmail.com
Abstract
PURPOSE: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). STUDY DESIGN/ METHODS: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. RESULTS: Mean age and number of injections were 72.9 +/- 11.99 years, and 2 +/- 0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09 +/- 0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98 +/- 0.55 (p = 0.59), 1.33 +/- 1.05 (p = 0.4) and 1.4 +/- 1.2 (p = 0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025 +/- 0.58 and mean visual acuity at 1, 3, and 6 months was 0.56 +/- 0.21 (p = 0.05), 0.61 +/- 0.17 (p = 0.03) and 0.66 +/- 0.34 (p = 0.12) respectively. Mean initial central macular thickness for the whole group was 527 +/- 182 microm and mean central macular thickness at 6 months was 379 +/- 156 microm (p < 0.001). CONCLUSION: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months.
PURPOSE: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). STUDY DESIGN/ METHODS: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. RESULTS: Mean age and number of injections were 72.9 +/- 11.99 years, and 2 +/- 0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09 +/- 0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98 +/- 0.55 (p = 0.59), 1.33 +/- 1.05 (p = 0.4) and 1.4 +/- 1.2 (p = 0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025 +/- 0.58 and mean visual acuity at 1, 3, and 6 months was 0.56 +/- 0.21 (p = 0.05), 0.61 +/- 0.17 (p = 0.03) and 0.66 +/- 0.34 (p = 0.12) respectively. Mean initial central macular thickness for the whole group was 527 +/- 182 microm and mean central macular thickness at 6 months was 379 +/- 156 microm (p < 0.001). CONCLUSION: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months.
Authors: Vincenzo Russo; Antonio Barone; Emanuele Conte; Francesco Prascina; Andrea Stella; Nicola Delle Noci Journal: Retina Date: 2009-04 Impact factor: 4.256
Authors: K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: Peter A Campochiaro; Gulnar Hafiz; Syed Mahmood Shah; Quan Dong Nguyen; Howard Ying; Diana V Do; Edward Quinlan; Ingrid Zimmer-Galler; Julia A Haller; Sharon D Solomon; Jennifer U Sung; Yasmin Hadi; Kashif A Janjua; Nida Jawed; David F Choy; Joseph R Arron Journal: Mol Ther Date: 2008-02-05 Impact factor: 11.454
Authors: Jason Hsu; Richard S Kaiser; Arunan Sivalingam; Prema Abraham; Mitchell S Fineman; Michael A Samuel; James F Vander; Carl D Regillo; Allen C Ho Journal: Retina Date: 2007-10 Impact factor: 4.256
Authors: Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: M Pfister; F H Koch; J Cinatl; F Rothweiler; R Schubert; P Singh; H Ackermann; M J Koss Journal: Ophthalmologe Date: 2013-08 Impact factor: 1.059
Authors: Young Hwan Bae; Seong Mi Kim; Jin Young Kim; So Hyun Bae; Hakyoung Kim; Dae Joong Ma Journal: J Ophthalmol Date: 2021-09-28 Impact factor: 1.909